{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:02:41Z","timestamp":1789383761400,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02336-0","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:42:32Z","timestamp":1789375352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Major cardiovascular event risk of advanced therapies in inflammatory bowel diseases: systematic review and meta-analysis"],"prefix":"10.1007","volume":"75","author":[{"given":"Amirah H.","family":"Alnahdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanxing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naueen","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianze","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"10114","key":"2336_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0.","journal-title":"Lancet"},{"issue":"1","key":"2336_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12664-023-01430-z","volume":"43","author":"K Dharni","year":"2024","unstructured":"Dharni K, Singh A, Sharma S, Midha V, Kaur K, Mahajan R, et al. Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990\u20132019). Indian J Gastroenterol. 2024;43(1):188\u201398. https:\/\/doi.org\/10.1007\/s12664-023-01430-z.","journal-title":"Indian J Gastroenterol"},{"issue":"5","key":"2336_CR3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","volume":"165","author":"JD Lewis","year":"2023","unstructured":"Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-1205.e2. https:\/\/doi.org\/10.1053\/j.gastro.2023.07.003.","journal-title":"Gastroenterology"},{"issue":"5","key":"2336_CR4","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1053\/j.gastro.2021.09.076","volume":"162","author":"C Le Berre","year":"2022","unstructured":"Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving short- and long-term goals of management of inflammatory bowel diseases: getting it right, making it last. Gastroenterology. 2022;162(5):1424\u201338. https:\/\/doi.org\/10.1053\/j.gastro.2021.09.076.","journal-title":"Gastroenterology"},{"issue":"22","key":"2336_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/eurheartj\/ehv759","volume":"37","author":"D Tousoulis","year":"2016","unstructured":"Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016;37(22):1723\u201335.","journal-title":"Eur Heart J"},{"issue":"3","key":"2336_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","volume":"12","author":"S Singh","year":"2014","unstructured":"Singh S, Singh H, Loftus EV, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(3):382-393.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2336_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","volume":"8","author":"M Fumery","year":"2014","unstructured":"Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohn\u2019s Colitis. 2014;8(6):469\u201379. https:\/\/doi.org\/10.1016\/j.crohns.2013.09.021.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"12","key":"2336_CR8","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1093\/rheumatology\/keac210","volume":"61","author":"AM Kerola","year":"2022","unstructured":"Kerola AM, Kazemi A, Rollefstad S, Lillegraven S, Sexton J, Wibetoe G, et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology. 2022;61(12):4656\u201366.","journal-title":"Rheumatology"},{"issue":"3","key":"2336_CR9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2336_CR10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/jdv.14951","volume":"32","author":"JJ Wu","year":"2018","unstructured":"Wu JJ, Joshi AA, Reddy SP, Batech M, Egeberg A, Ahlehoff O, et al. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol. 2018;32(8):1320\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2336_CR11","doi-asserted-by":"publisher","first-page":"2568569","DOI":"10.1155\/2018\/2568569","volume":"2018","author":"AG Gravina","year":"2018","unstructured":"Gravina AG, Dallio M, Masarone M, Rosato V, Aglitti A, Persico M, et al. Vascular endothelial dysfunction in inflammatory bowel diseases: pharmacological and nonpharmacological targets. Oxid Med Cell Longev. 2018;2018(1):2568569.","journal-title":"Oxid Med Cell Longev"},{"issue":"38","key":"2336_CR12","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","volume":"39","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499\u2013507.","journal-title":"Eur Heart J"},{"issue":"5","key":"2336_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/17474124.2023.2194631","volume":"17","author":"M Shehab","year":"2023","unstructured":"Shehab M, Alrashed F, Alkazemi A, Lakatos PL, Bessissow T. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol. 2023;17(5):469\u201377.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2336_CR14","unstructured":"Covidence. Covidence systematic review software. [Internet]. Covidence Systematic Review Software, Veritas Health Innovation, Melbourne, Australia. 2022. Available from: www.covidence.org."},{"issue":"1","key":"2336_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-021-01440-5","volume":"21","author":"E Bosco","year":"2021","unstructured":"Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21(1):1\u201318. https:\/\/doi.org\/10.1186\/s12874-021-01440-5.","journal-title":"BMC Med Res Methodol"},{"key":"2336_CR16","first-page":"1","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:1\u20138.","journal-title":"BMJ"},{"key":"2336_CR17","first-page":"1","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:1\u20137.","journal-title":"BMJ"},{"issue":"9","key":"2336_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing\u202f? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351\u201375.","journal-title":"Stat Med"},{"issue":"29","key":"2336_CR19","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1002\/sim.4040","volume":"29","author":"T Stijnen","year":"2010","unstructured":"Stijnen T, Hamza THP\u00d6. Random effects meta\u2010analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29(29):3046\u201367.","journal-title":"Stat Med"},{"issue":"10340","key":"2336_CR20","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015\u201330.","journal-title":"Lancet"},{"issue":"10340","key":"2336_CR21","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031\u201346.","journal-title":"Lancet"},{"key":"2336_CR22","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel J-F, et al. Manteniance infliximab in Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"issue":"2","key":"2336_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Van Assche G, Reinisch W, Colombel J, D\u2019Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-265.e3. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.032.","journal-title":"Gastroenterology"},{"issue":"2","key":"2336_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","volume":"49","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49(2):283\u201394.","journal-title":"J Gastroenterol"},{"issue":"3","key":"2336_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357(3):328\u201338.","journal-title":"N Engl J Med"},{"issue":"18","key":"2336_CR26","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for Ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336.","journal-title":"N Engl J Med"},{"issue":"13","key":"2336_CR27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314.","journal-title":"N Engl J Med"},{"issue":"2","key":"2336_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","volume":"6","author":"M Watanabe","year":"2012","unstructured":"Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn\u2019s disease. J Crohn\u2019s Colitis. 2012;6(2):160\u201373. https:\/\/doi.org\/10.1016\/j.crohns.2011.07.013.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"1","key":"2336_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","volume":"7","author":"DT Rubin","year":"2022","unstructured":"Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PD, et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022;7(1):17\u201327.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"10341","key":"2336_CR30","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113\u201328.","journal-title":"Lancet"},{"issue":"20","key":"2336_CR31","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"8","key":"2336_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"14","key":"2336_CR33","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as induction and maintenance therapy for Ulcerative colitis. N Engl J Med. 2021;385(14):1280\u201391.","journal-title":"N Engl J Med"},{"issue":"21","key":"2336_CR34","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus","year":"2023","unstructured":"Loftus EV, Pan\u00e9s J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388(21):1966\u201380.","journal-title":"N Engl J Med"},{"issue":"10292","key":"2336_CR35","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372\u201384.","journal-title":"Lancet"},{"issue":"5","key":"2336_CR36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","volume":"142","author":"P Rutgeerts","year":"2012","unstructured":"Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102-1111.e2. https:\/\/doi.org\/10.1053\/j.gastro.2012.01.035.","journal-title":"Gastroenterology"},{"issue":"6","key":"2336_CR37","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","volume":"60","author":"W Reinisch","year":"2011","unstructured":"Reinisch W, Sandborn WJ, Hommes DW, D\u2019Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780\u20137.","journal-title":"Gut"},{"issue":"1","key":"2336_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132(1):52\u201365.","journal-title":"Gastroenterology"},{"issue":"7","key":"2336_CR39","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1053\/j.gastro.2022.01.044","volume":"162","author":"GR D\u2019Haens","year":"2022","unstructured":"D\u2019Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L, et al. Higher vs standard adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results. Gastroenterology. 2022;162(7):1876\u201390. https:\/\/doi.org\/10.1053\/j.gastro.2022.01.044.","journal-title":"Gastroenterology"},{"issue":"7","key":"2336_CR40","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1053\/j.gastro.2022.02.033","volume":"162","author":"J Pan\u00e9s","year":"2022","unstructured":"Pan\u00e9s J, Colombel JF, D\u2019Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, et al. Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results. Gastroenterology. 2022;162(7):1891\u2013910.","journal-title":"Gastroenterology"},{"issue":"4","key":"2336_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","volume":"7","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, D\u2019Haens G, Pan\u00e9s J, Dignass A, Magro F, et al. Treat to target versus standard of care for patients with Crohn\u2019s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022;7(4):294\u2013306.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"2336_CR42","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial. J Crohns Colitis. 2021;15(7):1130\u201341.","journal-title":"J Crohns Colitis"},{"issue":"10342","key":"2336_CR43","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200\u201311.","journal-title":"Lancet"},{"issue":"13","key":"2336_CR44","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel J-F, T\u00f6r\u00fcner M, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215\u201326.","journal-title":"N Engl J Med"},{"issue":"9857","key":"2336_CR45","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","volume":"380","author":"D Laharie","year":"2012","unstructured":"Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909\u201315.","journal-title":"Lancet"},{"issue":"2","key":"2336_CR46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","volume":"18","author":"A Singh","year":"2024","unstructured":"Singh A, Midha V, Kaur K, Mahajan R, Singh D, Kaur R, et al. Tofacitinib vs. oral prednisolone for induction of remission in moderately active ulcerative colitis [ORCHID]: a prospective, open-label, randomized. Pilot Study J Crohn\u2019s Colitis. 2024;18(2):300\u20137.","journal-title":"Pilot Study J Crohn\u2019s Colitis"},{"issue":"11\u201312","key":"2336_CR47","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/apt.16119","volume":"52","author":"R Panaccione","year":"2020","unstructured":"Panaccione R, Danese S, Sandborn WJ, O\u2019Brien CD, Zhou Y, Zhang H, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020;52(11\u201312):1658\u201375.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2336_CR48","doi-asserted-by":"publisher","first-page":"910","DOI":"10.14309\/ajg.0000000000002621","volume":"119","author":"W Afif","year":"2024","unstructured":"Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, et al. Efficacy and safety of ustekinumab for ulcerative colitis through 4 years: final results of the UNIFI long-term maintenance study. Am J Gastroenterol. 2024;119(5):910\u201321.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2336_CR49","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","volume":"16","author":"MT Abreu","year":"2022","unstructured":"Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, et al. Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension. J CroMThn\u2019s Colitis. 2022;16(8):1222\u201334.","journal-title":"J CroMThn\u2019s Colitis"},{"issue":"1","key":"2336_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.14794","volume":"48","author":"WJ Sandborn","year":"2018","unstructured":"Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, et al. Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48(1):65\u201377.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2336_CR51","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, et al. Five-year efficacy and safety of Ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20(3):578-590.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2336_CR52","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.crohns.2014.04.012","volume":"8","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A, et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn\u2019s disease. J Crohns Colitis. 2014;8(11):1407\u201316.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2336_CR53","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","volume":"17","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, D\u2019Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme. J Crohns Colitis. 2023;17(3):338\u201351.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2336_CR54","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","volume":"55","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV, Hart A, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE open, an open-label, long-term extension study with up to 7.0\u00a0years of treatment. Aliment Pharmacol Ther. 2022;55(4):464\u201378.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"2336_CR55","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","volume":"17","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, Pan\u00e9s J, D\u2019Haens GR, Sands BE, Su C, Moscariello M, et al. Safety of Tofacitinib for treatment of Ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17(8):1541\u201350. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.035.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2336_CR56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cgh.2022.06.011","volume":"21","author":"L Dheyriat","year":"2023","unstructured":"Dheyriat L, Ward D, Beaugerie L, Jess T, Kirchgesner J. Risk of recurrent acute arterial events associated With thiopurines and anti-tumor necrosis factor in inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2023;21(1):164-172.e11. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.011.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2336_CR57","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/gutjnl-2019-318932","volume":"69","author":"J Kirchgesner","year":"2020","unstructured":"Kirchgesner J, Nyboe Andersen N, Carrat F, Jess T, Beaugerie L. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. Gut. 2020;69(5):852\u20138.","journal-title":"Gut"},{"issue":"11","key":"2336_CR58","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/rheumatology\/kem212","volume":"46","author":"JR Curtis","year":"2007","unstructured":"Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, et al. Heart failure among younger rheumatoid arthritis and Crohn\u2019s patients exposed to TNF-\u03b1 antagonists. Rheumatology. 2007;46(11):1688\u201393.","journal-title":"Rheumatology"},{"issue":"2","key":"2336_CR59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.gastrohep.2022.05.010","volume":"46","author":"C Amiama Roig","year":"2023","unstructured":"Amiama Roig C, Su\u00e1rez Ferrer C, Rueda Garc\u00eda JL, Poza Cord\u00f3n J, S\u00e1nchez-Azofra M, Mart\u00edn Arranz E, et al. Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2023;46(2):109\u201315.","journal-title":"Gastroenterol Hepatol"},{"issue":"10","key":"2336_CR60","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/apt.15706","volume":"51","author":"H Alric","year":"2020","unstructured":"Alric H, Amiot A, Kirchgesner J, Tr\u00e9ton X, Allez M, Bouhnik Y, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51(10):948\u201357.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2336_CR61","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","volume":"27","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Regueiro M, Yun H, Su C, Dibonaventura M, Lawendy N, et al. Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan\u00ae administrative claims database with tofacitinib trial data. Inflamm Bowel Dis. 2021;27(9):1394\u2013408.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"2336_CR62","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","volume":"67","author":"BD Kochar","year":"2022","unstructured":"Kochar BD, Cheng D, Cai T, Ananthakrishnan AN. Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases. Dig Dis Sci. 2022;67(11):5206\u201312.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2336_CR63","first-page":"94","volume":"5","author":"C Xu","year":"2024","unstructured":"Xu C, Lin L. The impact of studies with no events in both arms on meta-analysis of rare events\u202f: a simulation study using generalized linear mixed model. Res Methods Med Heal Sci. 2024;5(4):94\u2013103.","journal-title":"Res Methods Med Heal Sci"},{"issue":"2","key":"2336_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0056944","volume":"8","author":"SL Kristensen","year":"2013","unstructured":"Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen GV, Torp-Pedersen C, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death - a Danish nationwide cohort study. PLoS ONE. 2013;8(2):1\u20139.","journal-title":"PLoS ONE"},{"issue":"5","key":"2336_CR65","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","volume":"62","author":"C Rungoe","year":"2013","unstructured":"Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62(5):689\u201394.","journal-title":"Gut"},{"issue":"1","key":"2336_CR66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11938-019-00222-9","volume":"17","author":"C Ma","year":"2019","unstructured":"Ma C, Battat R, Jairath V, Vande CN. Advances in therapeutic drug monitoring for small-molecule and biologic therapies in inflammatory bowel disease. Curr Treat Opt Gastroenterol. 2019;17(1):127\u201345.","journal-title":"Curr Treat Opt Gastroenterol"},{"issue":"9318","key":"2336_CR67","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials\u202f: good practice and pitfalls. Lancet. 2002;359(9318):1686\u20139.","journal-title":"Lancet"},{"issue":"9","key":"2336_CR68","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/aje\/kwad091","volume":"192","author":"T Jiao","year":"2023","unstructured":"Jiao T, Platt RW, Douros A, Filion KB. Use of a statistical adaptive treatment strategy approach for emulating randomized Controlled trials using observational data: the example of blood-pressure control strategies for the prevention of cardiovascular events among individuals with hypertension. Am J Epidemiol. 2023;192(9):1576\u201391.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"2336_CR69","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","volume":"22","author":"SS Mattay","year":"2024","unstructured":"Mattay SS, Zamani M, Saturno D, Loftus EV, Ciorba MA, Yarur A, et al. Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis. Clin Gastroenterol Hepatol. 2024;22(5):961\u201370.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2336_CR70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib13010016","volume":"13","author":"T Velikova","year":"2024","unstructured":"Velikova T, Sekulovski M, Peshevska-Sekulovska M. Immunogenicity and loss of effectiveness of biologic therapy for inflammatory bowel disease patients due to anti-drug antibody development. Antibodies. 2024;13(1):16.","journal-title":"Antibodies"},{"issue":"8","key":"2336_CR71","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/diagnostics14080834","volume":"14","author":"P Anyfanti","year":"2024","unstructured":"Anyfanti P, Angeloudi E, Dara A, Pagkopoulou E, Moysidou GS, Deuteraiou K, et al. Non-invasive assessment of micro- and macrovascular function after initiation of JAK inhibitors in patients with rheumatoid arthritis. Diagnostics. 2024;14(8):834.","journal-title":"Diagnostics"},{"issue":"2","key":"2336_CR72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2023","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2023;83(2):139\u201360.","journal-title":"Ann Rheum Dis"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02336-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02336-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02336-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:03:35Z","timestamp":1789380215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02336-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02336-0","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no financial, professional, or personal conflicts of interest relevant to this manuscript to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"213"}}